RegeneRx Biopharmaceuticals, Inc. - Product Pipeline Review - 2012


#138291

62pages

Global Markets Direct

$ 1500

In Stock


RegeneRx Biopharmaceuticals, Inc. Product Pipeline Review 2012

Global Market Directs pharmaceuticals report, RegeneRx Biopharmaceuticals, Inc. Product Pipeline Review 2012 provides data on the RegeneRx Biopharmaceuticals, Inc.s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. 

This report is built using data and information sourced from Global Markets Directs proprietary databases, RegeneRx Biopharmaceuticals, Inc.s corporate website, SEC filings, investor presentations and featured press releases, both from RegeneRx Biopharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Directs team. 

Scope

  • RegeneRx Biopharmaceuticals, Inc. Brief RegeneRx Biopharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of RegeneRx Biopharmaceuticals, Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of RegeneRx Biopharmaceuticals, Inc. with complete description of the products developmental history, mechanism of action, therapeutic class, target and major milestones. 
  • Recent updates of the RegeneRx Biopharmaceuticals, Inc.s pipeline in the last quarter. 
  • Key discontinued and dormant projects. 
  • Latest news and deals relating to the products.

Reasons to buy

  • Evaluate RegeneRx Biopharmaceuticals, Inc.s strategic position with total access to detailed information on its product pipeline. 
  • Assess the growth potential of RegeneRx Biopharmaceuticals, Inc. in its therapy areas of focus. 
  • Identify new drug targets and therapeutic classes in the RegeneRx Biopharmaceuticals, Inc.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. 
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. 
  • Exploit collaboration and partnership opportunities with RegeneRx Biopharmaceuticals, Inc.. 
  • Avoid Intellectual Property Rights related issues. 
  • Explore the dormant and discontinued projects of RegeneRx Biopharmaceuticals, Inc. and identify potential opportunities in those areas.
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
RegeneRx Biopharmaceuticals, Inc. Snapshot 5
RegeneRx Biopharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
RegeneRx Biopharmaceuticals, Inc. – Research and Development Overview 6
Key Therapeutic Areas 6
RegeneRx Biopharmaceuticals, Inc. – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products –  Monotherapy 9
RegeneRx Biopharmaceuticals, Inc. – Pipeline Products Glance 10
RegeneRx Biopharmaceuticals, Inc. Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
RegeneRx Biopharmaceuticals, Inc. – Early Stage Pipeline Products 12
Pre-Clinical Products/Combination Treatment Modalities 12
RegeneRx Biopharmaceuticals, Inc. – Drug Profiles 13
RGN-137 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
RGN-259 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
RGN-352 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
RGN-457 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
RegeneRx Biopharmaceuticals, Inc. – Pipeline Analysis 18
RegeneRx Biopharmaceuticals, Inc. – Pipeline Products by Therapeutic Class 18
RegeneRx Biopharmaceuticals, Inc. – Pipeline Products by Route of Administration 19
RegeneRx Biopharmaceuticals, Inc. – Pipeline Products By Mechanism of Action 20
RegeneRx Biopharmaceuticals, Inc. –  Recent Pipeline Updates 21
RegeneRx Biopharmaceuticals, Inc. – Locations And Subsidiaries 25
Head Office 25
RegeneRx Biopharmaceuticals, Inc., Recent Developments 26
RegeneRx Biopharmaceuticals, Inc.- Press Release 26
Aug 29, 2012: RegeneRx Reports That Thymosin Beta 4 Promotes Recovery Of Peripheral Neuropathy In Type II Diabetic Mice 26
Jun 20, 2012: RegeneRx Reports Results From Phase II Clinical Trial Of RGN-259 For Treatment Of Severe Dry Eye 26
May 25, 2012: RegeneRx Announces Publication Of Tß4 Data In Journal Of Neurosurgery 27
Apr 18, 2012: Thymosin Beta 4 In Conjunction With Gene Therapy Enhances Process Of Converting Non-Beating Heart Cells Into Functional, Beating Heart Cells 28
Apr 09, 2012: RegeneRx Receives Four New Patents And Allowances In Mexico And Israel 28
Mar 20, 2012: RegeneRx Reports New Data On Thymosin Beta 4 At Third International Symposium On Thymosins In Health And Disease 29
Feb 15, 2012: Researchers Show RegeneRx's Tß4 Provides Both Neuroprotection And Neurorestoration After Traumatic Brain Injury 29
Feb 01, 2012: RegeneRx Explores Potential Strategic Partners For RGN-259 30
Jan 09, 2012: RegeneRx Receives Major US Heart Patent 30
Jan 05, 2012: RegeneRx Receives Clinical Study Report For Phase II Dry Eye Trial 30
Dec 09, 2009: RegeneRx Announces Phase I Trial Of RGN-352 For Cardiovascular Tissue Repair 31
Aug 24, 2009: RegeneRx Receives Notice Of Allowance In Europe For Key Patent Related To Inhibition And Reversal Of Skin Aging 32
May 04, 2009: RegeneRx Receives Australian Patent For Treating Eye Disorders With Tß4 32
Apr 04, 2009: RegeneRx Reports Tß4 Identified As A Key Molecule Capable Of Triggering Stem Cells To Repair Damaged Adult Heart 33
Mar 26, 2009: RegeneRx Reports Phase II Venous Stasis Trial Results 33
Mar 02, 2009: RegeneRx Completes Enrollment And Dosing Of Phase I Safety Trial For Potential Heart Drug 34
Feb 26, 2009: RegeneRx Updates On Phase II Venous Stasis Trial 35
Jan 21, 2009: RegeneRx Plans To Shifts Ophthalmic Clinical Development Strategy 35
Jan 09, 2009: RegeneRx Reports Phase II Pressure Ulcer Trial Results 35
Financial Deals Landscape 37
RegeneRx Biopharmaceuticals, Inc., Deals Summary 37
RegeneRx Biopharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details 38
Partnerships 38
RegeneRx BioPharma Plans To Enter Into Co-Development Agreement For RGN-259 38
RegeneRx BioPharma Enters Into Agreement With University of Maryland And University of Maryland 39
Licensing Agreements 40
RegeneRx Biopharma Enters Into Licensing Agreement With Lee's Pharma For RGN-259, RGN-352 And RGN-137 40
Equity Offering 42
RegeneRx BioPharma Completes Registered Direct Offering Of $1.45 Million 42
RegeneRx BioPharma Announces Private Placement Of $11 Million 45
RegeneRx BioPharma Completes Over-Allotment Option Of Public Offering For $5.4 Million 47
RegeneRx BioPharma Completes Private Placement Of $1 Million 49
RegeneRx BioPharma Completes Registered Direct Offering Of $3.7 Million 51
RegeneRx Completes Private Placement Of $3 Million 53
RegeneRx BioPharma Completes Private Placement Of $5 Million 55
RegeneRx Completes Private Placement Of $9.55 Million 57
RegeneRx BioPharma Completes Registered Direct Offering For $7.3 Million 59

Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 62
Disclaimer 62

RegeneRx Biopharmaceuticals, Inc., Key Information 5
RegeneRx Biopharmaceuticals, Inc., Key Facts 5
RegeneRx Biopharmaceuticals, Inc. Pipeline by Indication, 2012 7
RegeneRx Biopharmaceuticals, Inc. Pipeline by Stage of Development, 2012 8
RegeneRx Biopharmaceuticals, Inc. Monotherapy Products in Pipeline, 2012 9
RegeneRx Biopharmaceuticals, Inc. Phase II, 2012 10
RegeneRx Biopharmaceuticals, Inc. Phase I, 2012 11
RegeneRx Biopharmaceuticals, Inc. Pre-Clinical, 2012 12
RegeneRx Biopharmaceuticals, Inc. Pipeline By Therapeutic Class, 2012 18
RegeneRx Biopharmaceuticals, Inc. Pipeline By Route of Administration, 2012 19
RegeneRx Biopharmaceuticals, Inc. Pipeline Products By Mechanism of Action, 2012 20
RegeneRx Biopharmaceuticals, Inc. Recent Pipeline Updates, 2012 21
RegeneRx Biopharmaceuticals, Inc., Deals Summary 37
RegeneRx BioPharma Plans To Enter Into Co-Development Agreement For RGN-259 38
RegeneRx BioPharma Enters Into Agreement With University of Maryland And University of Maryland 39
RegeneRx Biopharma Enters Into Licensing Agreement With Lee\'s Pharma For RGN-259, RGN-352 And RGN-137 40
RegeneRx BioPharma Completes Registered Direct Offering Of $1.45 Million 42
RegeneRx BioPharma Announces Private Placement Of $11 Million 45
RegeneRx BioPharma Completes Over-Allotment Option Of Public Offering For $5.4 Million 47
RegeneRx BioPharma Completes Private Placement Of $1 Million 49
RegeneRx BioPharma Completes Registered Direct Offering Of $3.7 Million 51
RegeneRx Completes Private Placement Of $3 Million 53
RegeneRx BioPharma Completes Private Placement Of $5 Million 55
RegeneRx Completes Private Placement Of $9.55 Million 57
RegeneRx BioPharma Completes Registered Direct Offering For $7.3 Million 59
RegeneRx Biopharmaceuticals, Inc. Pipeline by Indication, 2012 7
RegeneRx Biopharmaceuticals, Inc. Pipeline by Stage of Development, 2012 8
RegeneRx Biopharmaceuticals, Inc. Monotherapy Products in Pipeline, 2012 9
RegeneRx Biopharmaceuticals, Inc. Pipeline By Therapeutic Class, 2012 18
RegeneRx Biopharmaceuticals, Inc. Pipeline By Route of Administration, 2012 19